Centessa Pharmaceuticals Poster Presentation at World Sleep 2025 in Singapore Sep 8, 2025 Supporting Materials Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750, for Treatment of Patients With Narcolepsy (Type 1 and 2) and Idiopathic Hypersomnia 650.1 KB
Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750, for Treatment of Patients With Narcolepsy (Type 1 and 2) and Idiopathic Hypersomnia 650.1 KB
